Seres Therapeutics
Stock Forecast, Prediction & Price Target
Seres Therapeutics Financial Estimates
Seres Therapeutics Revenue Estimates
Seres Therapeutics EBITDA Estimates
Seres Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $144.92M N/A | $7.12M -95.08% | $126.32M 1672.23% | Avg: $5M Low: $5M High: $5M avg. -96.04% | Avg: $85.13M Low: $85.13M High: $85.13M avg. 1602.76% | Avg: $32.26M Low: $32.26M High: $32.26M avg. -62.09% | Avg: $333.66M Low: $333.66M High: $333.66M avg. 933.99% |
Net Income
% change YoY
| $-61.49M N/A | $-253.82M -312.74% | $-113.72M 55.19% | Avg: $-146.31M Low: $-126.72M High: $-47.42M avg. -28.65% | Avg: $-42.50M Low: $-129.28M High: $88.32M avg. 70.95% | Avg: $-58.00M Low: $-58.00M High: $-58.00M avg. -36.47% | Avg: $286.95M Low: $286.95M High: $286.95M avg. 594.69% |
EBITDA
% change YoY
| $-62.66M N/A | $-244.13M -289.57% | $-85.43M 65.00% | Avg: $-4.16M Low: $-4.16M High: $-4.16M avg. 95.12% | Avg: $-70.86M Low: $-70.86M High: $-70.86M avg. -1602.76% | Avg: $-26.86M Low: $-26.86M High: $-26.86M avg. 62.09% | Avg: $-277.73M Low: $-277.73M High: $-277.73M avg. -933.99% |
EPS
% change YoY
| -$0.67 N/A | -$2.35 -250.74% | -$0.89 62.12% | Avg: -$0.72 Low: -$0.99 High: -$0.37 avg. 19.41% | Avg: -$0.07 Low: -$1.01 High: $0.69 avg. 90.28% | Avg: -$0.45 Low: -$0.45 High: -$0.45 avg. -550.63% | Avg: $2.24 Low: $2.24 High: $2.24 avg. 594.69% |
Operating Expenses
% change YoY
| $209.42M N/A | $253.61M 21.10% | $233.60M -7.89% | Avg: $13.99M Low: $13.99M High: $13.99M avg. -94.00% | Avg: $238.33M Low: $238.33M High: $238.33M avg. 1602.76% | Avg: $90.33M Low: $90.33M High: $90.33M avg. -62.09% | Avg: $934.02M Low: $934.02M High: $934.02M avg. 933.99% |
FAQ
What is Seres Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 150.12% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is -126.72M, average is -146.31M and high is -47.42M.
What is Seres Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 594.65% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $5M, average is $5M and high is $5M.
What is Seres Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 38.43% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$0.99, average is -$0.72 and high is $-0.37.
What is the best performing analyst?
In the last twelve months analysts have been covering Seres Therapeutics stock. The most successful analyst is Keay Nakae.